ArticleGeroScience2025
Exploring the power of MRI and clinical measures in predicting AD neuropathology.
Article in GeroScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Few-shot deployment of pretrained MRI transformers in brain imaging tasks.Frontiers in artificial intelligence · 2026Article
- Few-Shot Deployment of Pretrained MRI Transformers in Brain Imaging Tasks.Research square · 2025Article
- Identifying dementia neuropathology using low-burden clinical data.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Apathy progression is associated with brain atrophy and white matter damage in Parkinson's disease.Brain communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Predicting Alzheimer's disease (AD) pathology prior to clinical diagnosis is important for identifying individuals at high risk of developing AD dementia. However, there remains a gap in leveraging MRI and clinical data to predict AD pathology. This study examines a novel machine learning approach that integrates the combined vascular (white matter hyperintensities, WMHs) and structural brain changes (gray matter, GM) with clinical factors (cognitive scores) to predict post-mortem neuropathology. Participants from the Alzheimer's Disease Neuroimaging Initiative dataset (ADNI) and National Alzheimer's Coordinating Center (NACC) with both post-mortem neuropathology data and antemortem MRI and clinical data were included. Machine learning models were applied towards feature selection of the top seven MRI, clinical, and demographic data to identify the best performing set of variables that could predict postmortem neuropathology outcomes (i.e., neurofibrillary tangles, neuritic plaques, diffuse plaques, senile/amyloid plaques, and amyloid angiopathy). The best-performing neuropathology predictors from ADNI were then validated in NACC to compare results and ensure that the feature selection process did not lead to overfitting. In ADNI, the best-performing model included total and temporal lobe WMHs and achieved r = 0.87(RMSE = 0.62) during cross-validation for neuritic plaques. Overall, post-mortem neuropathology outcomes were predicted up to 14 years before death with high accuracies (~ 90%). Similar results were observed in the NACC dataset. These findings highlight that MRI features are critical to successfully predict AD-related pathology years in advance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.